Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3505-3509

  Kullar, Ravina ^a   Chin, Judy N ^a   Edwards, David J ^a   Parker, Dennis ^a,b,c   Coplin, William M ^b,c   Rybak, Michael J ^a,b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DAPTOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; BRAIN VENTRICULITIS; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID SHUNTING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG MEGADOSE; DRUG PENETRATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MENINGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BINDING; SINGLE DRUG DOSE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CENTRAL NERVOUS SYSTEM BACTERIAL INFECTIONS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAPTOMYCIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROSURGERY; PROSPECTIVE STUDIES;

EID: 79959194183     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01741-10     Document Type: Article

References (40)

1. Akins, R. L., and M. J. Rybak. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459.
2. Albanese, J., et al. 2000. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob. Agents Chemother. 44:1356-1358.
3. Arbeit, R. D., D. Maki, F. P. Tally, E. Campanaro, and B. I. Eisenstein. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38:1673-1681.
4. Benet, L. Z., and R. L. Galeazzi. 1979. Noncompartmental determination of the steady-state volume of distribution. J. Pharm. Sci. 68:1071-1074.
5. Benvenuto, M., D. P. Benziger, S. Yankelev, and G. Vigliani. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249.
6. Bradbury, M. W. 1984. The structure and function of the blood-brain barrier. Fed. Proc. 43:186-190.
7. Caricato, A., et al. 2006. Levels of vancomycin in the cerebral interstitial fluid after severe head injury. Intensive Care Med. 32:325-328. (Pubitemid 43251159)
8. Cottagnoud, P., et al. 2004. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob. Agents Chemother. 48:3928-3933.
9. de Louvois, J., P. Gortvai, and R. Hurley. 1977. Antibiotic treatment of abscesses of the central nervous system. Br. Med. J. ii:985-987.
10. Dvorchik, B. H., D. Brazier, M. F. DeBruin, and R. D. Arbeit. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323.
11. Dvorchik, B. H., and D. Damphousse. 2005. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J. Clin. Pharmacol. 45:48-56.
12. Egermann, U., et al. 2009. Combination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone. Antimicrob. Agents Chemother. 53:3030-3033.
13. Eisenstein, B. I. 2004. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin. Invest. Drugs 13:1159-1169.
14. Figueroa, D. A., et al. 2009. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin. Infect. Dis. 49:177-180.
15. Fowler, V. G., Jr., et al. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
16. Gerber, P., A. Stucki, F. Acosta, M. Cottagnoud, and P. Cottagnoud. 2006. Daptomycin is more efficacious than vancomycin against a methicillin- susceptible Staphylococcus aureus in experimental meningitis. J. Antimicrob. Chemother. 57:720-723.
17. Gnanalingham, K. K., A. Elsaghier, C. Kibbler, and C. Shieff. 2003. The impact of methicillin-resistant Staphylococcus aureus in a neurosurgical unit: a growing problem. J. Neurosurg. 98:8-13. (Pubitemid 36050441)
18. Humbert, G., A. Leroy, S. R. Nair, and C. E. Cherubin. 1984. Concentrations of cefotaxime and the desacetyl metabolite in serum and CSF of patients with meningitis. J. Antimicrob. Chemother. 13:487-494.
19. Karlsson, M., S. Hammers-Berggren, L. Lindquist, G. Stiernstedt, and B. Svenungsson. 1994. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 44:1203-1207. (Pubitemid 24232215)
20. Katz, D. E., et al. 2008. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int. J. Clin. Pract. 62:1455-1464.
21. Kim, A., et al. 2008. In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob. Agents Chemother. 52:3941-3946.
22. Korinek, A. M. 1997. Risk factors for neurosurgical site infections after craniotomy: a prospective multicenter study of 2944 patients. The French Study Group of Neurosurgical Infections, the SEHP, and the C-CLIN Paris-Nord. Service Epidemiologie Hygiene et Prevention. Neurosurgery 41:1073-1081.
23. Kullar, R., et al. High-dose daptomycin for complicated Gram-positive infections, poster P1984. Progr. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis., Helsinki, Finland, 16 to 19 May 2009.
24. Kullar, R., et al. 2011. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 31:527-536.
25. Lietard, C., V. Thebaud, G. Besson, and B. Lejeune. 2008. Risk factors for neurosurgical site infections: an 18-month prospective survey. J. Neurosurg. 109:729-734.
26. Lipman, J., A. Allworth, and S. C. Wallis. 2000. Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. Clin. Infect. Dis. 31:1131-1133.
27. Lutsar, I., G. H. McCracken, Jr., and I. R. Friedland. 1998. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin. Infect. Dis. 27:1117-1127, 1128-1129.
28. Mohr, J. F., L. V. Friedrich, S. Yankelev, and K. C. Lamp. 2009. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int. J. Antimicrob. Agents 33:543-548.
29. Moise, P. A., E. Hershberger, M. I. Amodio-Groton, and K. C. Lamp. 2009. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann. Pharmacother. 43:1211-1219.
30. Nau, R., F. Sorgel, and H. Eiffert. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 23:858-883.
31. Pai, M. P., et al. 2007. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob. Agents Chemother. 51:2741-2747.
32. Pfausler, B., et al. 2003. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J. Neurosurg. 98:1040-1044. (Pubitemid 36460895)
33. Pfister, H. W., V. Preac-Mursic, B. Wilske, and K. M. Einhaupl. 1989. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. Arch. Neurol. 46:1190-1194.
34. Ricard, J. D., et al. 2007. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin. Infect. Dis. 44:250-255.
35. Riser, M. S., C. M. Bland, C. N. Rudisill, and P. B. Bookstaver. Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis. Ann. Pharmacother 44:1832-1835.
36. Rockowitz, J., and A. R. Tunkel. 1995. Bacterial meningitis. Practical guidelines for management. Drugs 50:838-853.
37. Rose, W. E., et al. 2008. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 52:831-836.
38. Sellner, J., M. G. Tauber, and S. L. Leib. Pathogenesis and pathophysiology of bacterial CNS infections. Handb. Clin. Neurol. 96C:1-16.
39. van der Valk, P. G., E. J. Kraai, P. C. van Voorst Vader, H. Haaxma-Reiche, and J. A. Snijder. 1988. Penicillin concentrations in cerebrospinal fluid (CSF) during repository treatment regimen for syphilis. Genitourin. Med. 64:223-225.
40. Zunt, J. R. Infections of the central nervous system in the neurosurgical patient. Handb. Clin. Neurol. 96C:125-141.